First-of-its-kind prospective trial evaluates the association between dd-cfDNA and clinical outcomes in heart transplantation using Prospera™ Heart with Donor Quantity Score (DQS) AUSTIN, Texas / Mar 25, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced that it will share results from the DEFINE-HT study in a late-breaking oral presentation at the... Read More